Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 11/20 | 0.33 |
| ▸ | S100A9 | P06702 | 1/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | KIT | P10721 | 1/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
| ▸ | FRK | P42685 | 1/20 | 0.31 |
| ▸ | SIK1 | P57059 | 1/20 | 0.31 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.31 |
| ▸ | SRMS | Q9H3Y6 | 1/20 | 0.31 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7214036 | 0.81 | HTT (0.49) | KDM4EALDH1A1LMNAGAAL3MBTL1 | |
| SCHEMBL18369621 | 0.79 | LRRK2 (0.38) | KDM4EALDH1A1LMNAGAAL3MBTL1 | |
| SCHEMBL19349693 | 0.76 | BRAF (0.48) | KITBRAFFRKSIK1MAP2K5 | |
| SCHEMBL23479603 | 0.73 | NUDT1 (0.30) | — | |
| SCHEMBL23473993 | 0.73 | PDK2 (0.35) | KDM4EHTT | |
| SCHEMBL16537147 | 0.73 | DYRK1B (0.44) | KDM4EALDH1A1LMNALRRK2FRK | |
| SCHEMBL17787159 | 0.72 | BTK (0.40) | LRRK2KIT | |
| SCHEMBL29881388 | 0.72 | BTK (0.40) | LRRK2KIT | |
| SCHEMBL28582601 | 0.70 | BRAF (0.33) | BRAF | |
| SCHEMBL4146041 | 0.69 | ADORA2A (0.42) | LRRK2RIPK1AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376443-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250368604-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250129020-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-04-24 | — | — | US | disclosed |
| CN-119350433-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2025-01-24 | — | — | CN | disclosed |
| US-12195427-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2025-01-14 | — | — | US | disclosed |
| CN-112867706-B | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-118373875-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-07-23 | — | — | CN | disclosed |
| CN-117964684-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117964683-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-05-03 | — | — | CN | disclosed |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-11584714-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-02-21 | — | — | US | disclosed |
| US-11584714-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-02-21 | — | — | US | disclosed |
| CN-112867706-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2021-05-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584714-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | KDM4E 4128/4885ALDH1A1 4701/4885LMNA 3465/4885 |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | KDM4E 4128/4885ALDH1A1 4701/4885LMNA 3465/4885 |
| US-20250368604-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | KDM4E 4128/4885ALDH1A1 4701/4885LMNA 3465/4885 |
| US-12195427-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | KDM4E 4128/4885ALDH1A1 4701/4885LMNA 3465/4885 |
| US-20250376443-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | KDM4E 4206/4885ALDH1A1 4718/4885LMNA 3016/4885 |
| US-20250129020-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | KDM4E 4128/4885ALDH1A1 4701/4885LMNA 3465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.